| Diane Harris Lcsw Cadc Llc | |
|
201 Main St Ste 2 Westbrook ME 04092-4763 | |
| (207) 653-7885 | |
| Not Available |
| Full Name | Diane Harris Lcsw Cadc Llc |
|---|---|
| Speciality | Social Worker |
| Location | 201 Main St Ste 2, Westbrook, Maine |
| Authorized Official Name and Position | Diane Harris (THERAPIST) |
| Authorized Official Contact | 2076537885 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Diane Harris Lcsw Cadc Llc 15 Running Brook Rd Windham ME 04062-5160 Ph: (207) 653-7885 | Diane Harris Lcsw Cadc Llc 201 Main St Ste 2 Westbrook ME 04092-4763 Ph: (207) 653-7885 |
| NPI Number | 1447035530 |
|---|---|
| Provider Enumeration Date | 08/28/2023 |
| Last Update Date | 08/28/2023 |
| Certification Date | 08/28/2023 |
| Medicare PECOS PAC ID | 5294185856 |
|---|---|
| Medicare Enrollment ID | O20231221002960 |
News Archive
EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.
Researchers from the University of California, San Diego, have found that mutations present in the sperms of the father could be predictors of autism in the offspring, in a landmark study. These mutations, if quantified could help ascertain the risk say the researchers. The new study appears this week in the latest issue of the journal Nature Medicine.
CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.
The National Institute on Aging of the National Institutes of Health awarded a $4.23 million grant to establish the Cleveland Alzheimer's Disease Research Center.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447035530 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Provider Name | Diane M Harris |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1184734170 PECOS PAC ID: 4880796333 Enrollment ID: I20070301000312 |
News Archive
EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.
Researchers from the University of California, San Diego, have found that mutations present in the sperms of the father could be predictors of autism in the offspring, in a landmark study. These mutations, if quantified could help ascertain the risk say the researchers. The new study appears this week in the latest issue of the journal Nature Medicine.
CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.
The National Institute on Aging of the National Institutes of Health awarded a $4.23 million grant to establish the Cleveland Alzheimer's Disease Research Center.
› Verified 7 days ago
News Archive
EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.
Researchers from the University of California, San Diego, have found that mutations present in the sperms of the father could be predictors of autism in the offspring, in a landmark study. These mutations, if quantified could help ascertain the risk say the researchers. The new study appears this week in the latest issue of the journal Nature Medicine.
CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.
The National Institute on Aging of the National Institutes of Health awarded a $4.23 million grant to establish the Cleveland Alzheimer's Disease Research Center.
› Verified 7 days ago
Easy Life Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 77 Mechanic St, Westbrook, ME 04092 Phone: 207-245-5861 | |
Destiny Residential Care, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 15 Teri Cir Apt 82, Westbrook, ME 04092 Phone: 207-317-7828 | |
Q2 Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 116 W Pleasant St, Westbrook, ME 04092 Phone: 207-210-9714 | |
Mint Condition Counseling, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 40 Brackett St Apt 3, Westbrook, ME 04092 Phone: 603-860-4900 | |
Smooth Home Care Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 186 Mechanic St, Westbrook, ME 04092 Phone: 207-409-7502 | |
Woodfords Family Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 15 Saunders Way, Westbrook, ME 04092 Phone: 207-878-9663 Fax: 207-878-2259 | |
Woodfords Family Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 15 Saunders Way, Westbrook, ME 04092 Phone: 207-878-9663 Fax: 207-878-2259 |